Data also showed that deregulated STAT3 and STAT5 activity promotes drug resistance in leukemias/lymphomas/myelomas, highlighting the crucial interest to develop pharmacological molecules that selectively target STAT3 and/or STAT5 in hematologic cancers. This evidence concerns the gene STAT5B and hematopoietic and lymphoid cell neoplasm.